SENSEX NIFTY
FDC > Company History > Pharmaceuticals > Company History of FDC - BSE: 531599, NSE: FDC
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - FDC
FDC
BSE: 531599|NSE: FDC|ISIN: INE258B01022|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Aug 22, 14:18
146.15
-2.7 (-1.81%)
VOLUME 32,585
LIVE
NSE
Aug 01, 17:00
141.60
1.1 (0.78%)
VOLUME 93,188
Company History - FDC
1940
 
 - The Company was Incorporated as a private limited company on 23rd
 September and converted into public limited company on 16th Sept.
 1988.  The Company was promoted as a partnership firm in 1936 by
 Late
 Mr. Anand Chandavarkar for the import of pharmaceutical dosage
 forms,
 specialised infant foods and surgical goods.  It was converted into
 a
 Pvt. Ltd. Company under the name Fairdeal Corporation Pvt. Ltd. in
 Mumbai.
 
 1949 
 
 - A formulation unit was set up at Jogeshwari.
 
 - During the mid seventies, the Company went in for a backward
 integration by setting up a unit for manufacture of basic drugs at
 Roha.
 
 1985 
 
 - Effective 24th June, the name of the Company was changed to FDC
 Pvt.
 Ltd.
 
 1991 
 
 - A biotechnology based R & D division was set up at Waluj.  Bulk
 drugs
 one formulated into injectables, tablets and capsules at the
 Jogeshwari
 Plant.
 
 1993
 
 - The Company commissioned a new unit at Waluj for manufacture of
 ophthalmic products using the labour from latest form/fill/seal
 technology.
 
 1995
 
 - 72,75,000 No. of equity shares issued to promoters, directors etc.
 27,28,200 No. of equity shares were issued at a premium of Rs 90 per
 share on 29th January 1996 of which 1,00,000 shares reserved and
 allotted to Directors, their friends, relatives and associates.  Of
 the
 remaining 15,000 shares to UTI on firm allotment.
 
 - Another 1,12,400 shares issued to employees on preferential basis
 (only 53,000 shares taken up).  Balance 25,00,800 shares issued to
 the
 public along with 59,400 shares from employees quota (13,36,980
 shares
 taken up).
 
 1996 
 
 - The Company introduced for the first time a unique dosage form of
 ophthalmics in the form of unit dose without preservating.
 
 - A modern biotechnology Lab was set up at Jogeshwari for Research
 and
 Development.
 
 - The Company proposed to give a major thrust on computerisation by
 switching over from the existing modular hardware and software on to
 an
 integrated RDBMS to facilitate dissemination of information
 throughout
 the organisation.
 
 - It was also proposed to set up a communication network by
 acquiring
 VSATS for linking all existing units with Corporate Office.
 
 - Fresh capacities were proposed to be built up for bull drugs viz.,
 cinnarizone at 500 Kgs p.a. and Floravizine at 120 kgs. per annum.
 
 - The Company undertook to technically upgrade the capacity in the
 ophthalmic dosages segment by installing a Form-fill-seal (FFS)
 machine
 at its plant in Waluj.
 
 - The Company undertook to set up two independent units adjacent to
 each other at Sinnar, Nasik for manufacture of penicillin based
 antibiotic formulations including sterile injectables, tablets,
 capsules etc.
 
 2000 
 
 - The company has launched Reliter, a dietart supplement for people
 over 49 with active lifestyles.
 
 2001 
 
 - The Rs. 150 crore FDC, best-known for its rehydration sale
 electral
 has tied up with Aspen Pharmacre to sell its ophthalmic products in
 South Africa.
 
 - FDC Ltd, makers of the popular Electral brand, has launched Simyl
 MCTOil -- a naturitional supplement for children and adults
 suffering
 from inadequate fat absorption.
 
 - The Company has launched Simyl MCT Oil, claimed to be unique
 nutritional supplement for children and adults suffering from
 inadequate fat absorption.
 
 2002
 
 -Ms Shalini Shenoy is appointed as the Compliance Officer  of the
 company.
 
 
 2003
 - Received GMP accreditation from the Medicines Control Council (MCC)
 of the Republic of South Africa, for registration of Oral powders and
 Sterile Ophthalmic dosages.
 
 -Mr. Rohit R Chandavarkar, the Company's Wholetime Director has
 passed away on October 29, 2003.
 
 2005
 
 -FDC receives CE mark approval for its 2 products from DNV - Norway
 
 2009
 
 - Fdc Ltd has appointed Mr. Ameya A. Chandavarkar, as a whole time
 director of the Company w.e.f. November 01, 2009.
 
 2010
 
 -Fdc Limited have recommended a dividend of Rs.1.75/- per equity
 share (175%).
 
 2011
 
 -FDC's Ophthalmic facility at Waluj, Aurangabad continues to be
 approved by UK MHRA 
 -FDC receives approval (Marketing Authorization) for Dorzolamide 2%
 w/v Eye Drop Solution and Dorzolamide 2% w/v & Timolol Maleate 0.5%
 w/v Eye Drop Solution from UKMHRA (RMS) under Decentralised
 Procedure. 
 
 -FDC receives Certificate of Appreciation Patents award from
 Pharmexcil
 
 2012
 
 -FDC Ltd is pleased to announce that it has received its first Indian
 Biotech Patent for the invention entitled METHOD FOR DETERMINING THE
 POTENCY OF G-CSF.
 
 -Fdc Ltd has appointed Mr. Vinod G. Yennemadi as an Additional
 Director on the Board of the Company.
Source : Dion Global Solutions Limited
Quick Links for FDC
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.